Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire Explores Robotic Pill Potential For Hemophilia

Executive Summary

The company has linked up with Rani Therapeutics to develop a simple-to-swallow capsule that is able to provide an alternative to current injectable therapies for hemophilia A.

You may also be interested in...



Finance Watch: VC Mega-Rounds Fund Wide Array, From Respiratory To Rare Diseases

Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.

Shire Snags EU Okay For Von Willebrand Drug Veyvondi

Although noises are still being made in Japan concerning the benefits of Shire's merger with Takeda, the former is going about the business of getting marketing green lights with the latest being for its inherited bleeding disorder treatment Veyvondi in Europe.

Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases

The appointment of Andreas Busch as its new head of R&D represents a boost for Shire which has 17 programs in late-stage development, headed by the potential HAE blockbuster SHP643.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel